Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
CARNMT1 antisense RNA 1 (CARNMT1-AS1) is a long noncoding RNA (lncRNA) gene transcribed in antisense orientation relative to the CARNMT1 gene. While the protein-coding gene CARNMT1 encodes carnosine N-methyltransferase 1, a methyltransferase involved in histidine N1-methylation of dipeptides and certain RNA-binding proteins, the functions of CARNMT1-AS1 itself have not been well characterized in the public literature or major gene annotation resources. Such antisense RNAs commonly regulate their sense counterpart gene expression via various mechanisms, but specific functions, clinical significance, or disease relations of CARNMT1-AS1 remain currently undefined[4]. Key points supporting this assessment: - CARNMT1-AS1 is listed in gene databases as an RNA gene, not encoding a protein product, and there is no evidence of it being a therapeutic target (such as receptor, enzyme, transporter, etc.)[4]. - There are no listed drugs targeting CARNMT1-AS1, no mechanism of action for therapeutic agents, and it is not described as a biomarker or associated with specific diseases in current resources[4]. - These features differentiate it sharply from CARNMT1 protein, for which considerable biochemical and biological role detail is available, notably as a methyltransferase with roles in RNA and protein modification[1][2]. If you require information about the protein CARNMT1 (carnosine N-methyltransferase 1), please clarify, as it is a separate entity with direct biological and potential therapeutic significance[1][2].
Not applicable (no drugs or therapeutic targeting described)
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on CARNMT1 antisense RNA 1 (CARNMT1-AS1).